Anti-reflux pharmacotherapy
PreclinicalSmall molecule
Anti-reflux pharmacotherapy is one of 10 small molecule programs targeting Lung Transplantation. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Lung Transplantation
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Opsumit
Johnson & JohnsonApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Calciparine
BBaxter Healthcare Corporation
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Imuran
LLegacy Health System
Approved
Tavalisse
RRigel Pharmaceuticals
Approved
Rezurock
KKadmon, a Sanofi Company
Approved
Hyperpolarized Xenon Gas
UUniversity of North Carolina, Chapel Hill
Preclinical
Anti-reflux pharmacotherapy
BBayside Health
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-reflux pharmacotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBayside Health